Product
Dasatinib
Aliases
BMS-354825, Dasatinib 100 MG, Dasatinib (BMS-354825), Dasatinib Hydrate (5 other aliases)
Name
SPRYCEL
FDA Approved
Yes
78 clinical trials
1 organization
1 drug
145 indications
1 document
Indication
Acute Myeloid LeukemiaIndication
Chronic Myelogenous LeukemiaIndication
LeukemiaIndication
MyelogenousIndication
ChronicIndication
BCR-ABL positiveIndication
cancerIndication
Non-small Cell LungIndication
Acute Lymphoblastic LeukemiaIndication
CancerIndication
Chronic Myeloid LeukaemiaIndication
Chronic Myeloid LeukemiaIndication
BCR-ABL1-positiveIndication
Philadelphia Chromosome PositiveIndication
PediatricIndication
Mixed Phenotype Acute LeukemiaIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Recurrent Mixed Phenotype Acute LeukemiaIndication
Breast CancerIndication
Non-Hodgkin lymphomaIndication
HIV InfectionIndication
GlioblastomaIndication
Recurrent DiseaseIndication
ObesityIndication
Healthy LifestyleIndication
Prostate CancerIndication
B-cell Acute Lymphoblastic LeukemiaIndication
Ph+ ALLIndication
HIV-1 InfectionIndication
Myelodysplastic SyndromesIndication
Primary MyelofibrosisIndication
MyelofibrosisIndication
Hypereosinophilic SyndromeIndication
Polycythemia VeraIndication
MastocytosisIndication
MyelomonocyticIndication
lymphomaIndication
chronic kidney diseaseIndication
MRDIndication
Breast Cancer, Stage IVIndication
Mild Cognitive ImpairmentIndication
Alzheimer's diseaseIndication
BCR-ABL1-likeIndication
Testicular LeukemiaIndication
Acute lymphoblastic leukemia, adult typeIndication
Adult L1 Acute Lymphoblastic LeukemiaIndication
Adult T Acute Lymphoblastic LeukemiaIndication
Adult Acute Lymphoblastic LeukemiaIndication
Waldenstrom MacroglobulinemiaIndication
dasatinibIndication
Colorectal CancerIndication
Colorectal cancerIndication
Colorectal Cancer stage IV AJCC v8Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Indication
Colon CancerIndication
Rectal CancerIndication
Stage III Colon CancerIndication
Esophageal cancerIndication
Pancreatic CancerIndication
Bile Duct CancerIndication
Stomach CancerIndication
Gallbladder CancerIndication
Small Bowel AdenocarcinomaIndication
T-cell Acute Lymphoblastic LeukemiaIndication
T-cell LymphomaIndication
AnaemiaIndication
Hodgkin lymphomaIndication
Non-Hodgkin LymphomaIndication
Hodgkin Lymphoma, Ann Arbor Stage IVIndication
Stage IV Non-Hodgkin LymphomaIndication
Atypical chronic myeloid leukemiaIndication
BCR-ABL1 NegativeIndication
Blast Phase Chronic Myelogenous LeukemiaIndication
Castration-Resistant Prostate CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Refractory Chronic Lymphocytic LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
Refractory Hematologic MalignancyIndication
Hodgkin's LymphomaIndication
Malignant Solid NeoplasmIndication
Myelodysplastic SyndromeIndication
UnclassifiableIndication
Recurrent Acute Myeloid LeukemiaIndication
Chronic Lymphocytic LeukemiaIndication
Recurrent Hematologic MalignancyIndication
Hodgkin LymphomaIndication
Myeloproliferative NeoplasmIndication
Multiple MyelomaIndication
Small Lymphocytic LymphomaIndication
Stage III Pancreatic CancerIndication
Refractory Non-Hodgkin LymphomaIndication
Pancreatic AdenocarcinomaIndication
Acute Lymphoblastic LymphomaIndication
BCR-ABL1 PositiveIndication
Triple-negative Breast CancerIndication
Myeloid LeukemiaIndication
Ph-Like Acute Lymphoblastic LeukemiaIndication
Endometrial Clear Cell AdenocarcinomaIndication
Clear Cell Ovarian CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Uterine Corpus CancerIndication
Lymphoblastic LymphomaIndication
HealthyIndication
Solid TumorsIndication
myeloidIndication
Advanced CancersIndication
CBF Acute Myeloid LeukemiaIndication
Therapy-Related Acute Myeloid LeukemiaIndication
Stage IV Pancreatic CancerIndication
Malignant NeoplasmIndication
Brain NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Stem Cell TransplantIndication
BCR-ABL1 Fusion Protein ExpressionIndication
t(9;22)Indication
AgingIndication
Chronic PhaseIndication
WithdrawalDrug
DasatinibIndication
Refractory Acute LeukemiaIndication
Acute LeukemiaIndication
Bi-phenotypic leukemiaIndication
EGFR gene mutationIndication
NSCLCClinical trial
An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420 as a Single Agent in Hematologic and Molecular Relapsed/Refractory Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2023-08-09
Clinical trial
Phase II Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationStatus: Terminated, Estimated PCD: 2014-07-23
Clinical trial
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued TreatmentStatus: Recruiting, Estimated PCD: 2027-08-27
Clinical trial
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Completed, Estimated PCD: 2021-06-03
Clinical trial
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid LeukemiaStatus: Completed, Estimated PCD: 2023-07-22
Clinical trial
A Phase II Study to Determine the Activity of Dasatinib Administered Orally (PO) at a Dose of 100 mg Once Daily (QD) in Chronic Phase Chronic Myelogenous Leukemia (CML), at a Dose of 70 mg Twice Daily (BID) in Advanced Phase Chronic Myelogenous Leukemia (CML) Chinese Subjects Who Are Resistant to or Intolerant of Imatinib Mesylate (Gleevec®)Status: Completed, Estimated PCD: 2009-06-17
Clinical trial
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibStatus: Completed, Estimated PCD: 2022-05-15
Clinical trial
Retrospective, Non-interventional Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund DatabaseStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREEStatus: Completed, Estimated PCD: 2017-09-20
Clinical trial
A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in VivoStatus: Completed, Estimated PCD: 2018-10-03
Clinical trial
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to ImatinibStatus: Active (not recruiting), Estimated PCD: 2016-09-01
Clinical trial
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg ImatinibStatus: Completed, Estimated PCD: 2017-11-08
Clinical trial
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib and Venetoclax: A Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2040-12-31
Clinical trial
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)Status: Completed, Estimated PCD: 2024-02-01
Clinical trial
Multi-center Clinical Trial for Optimal Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in KoreaStatus: Not yet recruiting, Estimated PCD: 2029-12-31
Clinical trial
A Dose-Finding Phase Ib Study of the Oral BCL-2 Inhibitor Venetoclax (ABT-199) in Combination With Standard Induction Therapy, Dasatinib, Prednisone, (and Rituximab in CD20+ Patients) in Adult Patients With Newly Diagnosed and Relapsed Philadelphia Chromosome Positive ALL (Ph+ ALL) and Ph+ MPALStatus: Recruiting, Estimated PCD: 2025-06-02
Clinical trial
A Phase II Study Using a BFM Regimen Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus: Withdrawn, Estimated PCD: 2026-01-01
Clinical trial
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)Status: Active (not recruiting), Estimated PCD: 2022-06-01
Clinical trial
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)Status: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
Phase II Study Assessing Safety and Clinical Activity of the Combination of ASTX727 With Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Status: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Phase I/II Study of Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (BMS Protocol 180129)Status: Completed, Estimated PCD: 2016-08-01
Clinical trial
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral TreatmentStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Evaluation of DASATINIB Monotherapy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINEStatus: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
Single Nuclei RNA-sequencing to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted TherapiesStatus: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 InfectionStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)Status: Completed, Estimated PCD: 2017-03-03
Clinical trial
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and NavitoclaxStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)Status: Completed, Estimated PCD: 2012-11-01
Clinical trial
Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic AgentsStatus: , Estimated PCD: 2025-04-01
Clinical trial
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseStatus: Recruiting, Estimated PCD: 2028-08-31
Clinical trial
Phase Ib/II Study of EPA-Based EphA2 Targeted Therapy for Patients With Metastatic Triple-Negative Inflammatory Breast CancerStatus: Terminated, Estimated PCD: 2023-12-19
Clinical trial
KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)Status: Active (not recruiting), Estimated PCD: 2016-06-01
Clinical trial
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's DiseaseStatus: , Estimated PCD: 2024-12-01
Clinical trial
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive MutationsStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Phase 1b Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on IbrutinibStatus: Terminated, Estimated PCD: 2021-12-31
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabStatus: Active (not recruiting), Estimated PCD: 2023-06-22
Clinical trial
SJALL23T: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)Status: Not yet recruiting, Estimated PCD: 2027-12-01
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Clinical trial
Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Bioequivalence Studies of Dasatinib 100 mg Tablets in Healthy Colombian Subjects in Postprandial ConditionStatus: Not yet recruiting, Estimated PCD: 2023-12-20
Clinical trial
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-11-28
Clinical trial
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsStatus: Terminated, Estimated PCD: 2019-09-24
Clinical trial
a Pilot Study to Explore the Efficacy and Safety of Dasatinib Combined With Quercetin to Reverse Chemotherapy Resistance in Triple Negative Breast Cancer.Status: Not yet recruiting, Estimated PCD: 2024-12-31
Clinical trial
Frontline Asciminib Combination in Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)Status: Completed, Estimated PCD: 2023-03-31
Clinical trial
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)Status: Terminated, Estimated PCD: 2021-01-20
Clinical trial
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in AdultsStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a ExpressionStatus: Terminated, Estimated PCD: 2017-02-06
Clinical trial
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid TumorsStatus: Completed, Estimated PCD: 2017-12-18
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Clinical trial
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.Status: Active (not recruiting), Estimated PCD: 2023-06-06
Clinical trial
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2010-11-01
Clinical trial
PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC ObstructionStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOGStatus: Completed, Estimated PCD: 2017-11-14
Clinical trial
A Phase I/II Trial of Dasatinib in Combination With Trastuzumab and Paclitaxel in the First Line Treatment of Her2-Positive Metastatic Breast Cancer (MBC) PatientsStatus: Completed, Estimated PCD: 2013-12-01
Clinical trial
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)Status: Completed, Estimated PCD: 2021-04-06
Clinical trial
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib (NSC #732517) and Continuation Therapy With Dasatinib Alone in Newly Diagnosed Patients With Core Binding Factor Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2013-07-01
Clinical trial
A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic CarcinomaStatus: Active (not recruiting), Estimated PCD: 2017-09-06
Clinical trial
A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus, and Cyclophosphamide in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2038-12-31
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Dasatinib in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2024-02-02
Clinical trial
Senolytics To Alleviate Mobility Issues and Neurological Impairment in AgingStatus: Completed, Estimated PCD: 2024-01-24
Clinical trial
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular RemissionStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic LeukemiaStatus: Not yet recruiting, Estimated PCD: 2030-12-01
Clinical trial
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasStatus: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR MutationsStatus: Terminated, Estimated PCD: 2018-08-01
Document
DailyMed Label: SPRYCELOrganization
E.R. Squibb & Sons, L.L.C.